Table 2.

Immunogenicity at 28 days after the second dose among the seronegative participants with a blood sample taken at this timepoint

	Aged 12–17 years, 28-day interval, GM		Aged 12–17 years, 112-day interval, GM		Aged 6–11 years, 112-day interval, GM		GMR (95% CI)*	GMR (95% CI)†
	ChAdOx1 nCoV-19 (n=45)	MenB vaccine (n=13)	ChAdOx1 nCoV-19 (n=46)	MenB vaccine (n=10)	ChAdOx1 nCoV-19 (n=48)	MenB vaccine (n=9)
Anti-spike by PPD (AU/mL)	43 280 (35 852–52 246); 45	73 (33–160); 13	73 371 (58 685–91 733); 45	227 (17–3072); 10	108 924 (84 852–139 823); 48	32 (16–61); 9	1·70 (1·27–2·26)	1·48 (1·07–2·07)
Anti-spike in-house (EU/mL)	1194 (908–1568); 45	4 (2–10); 13	1963 (1575–2448); 45	9 (1–106); 10	2377 (1773–3185); 48	2 (1–2); 9	1·64 (1·16–2·33)	1·21 (0·84–1·74)
PseudoNA (IC50)	150 (116–194); 45	20 (20–20); 13	299 (230–390); 44	57 (11–280); 10	885 (614–1275); 48	20 (20–20); 9	1·99 (1·39–2·86)	2·96 (1·89–4·62)
ELISpot in-house (SFC per 106 PBMCs)	270 (196–372); 39	22 (15–32); 10	135 (96–190); 36	30 (12–77); 8	104 (79–137); 39	19 (12–32); 6	0·50 (0·31–0·79)	0·77 (0·50–1·19)
Anti-receptor-binding domain by PPD (AU/mL)	49 764 (41 278–59 995); 45	150 (99–228); 13	92 520 (73 068–117 151); 45	445 (41–4805); 10	140 413 (108 182–182 247); n=48	102 (102–102); 9	1·86 (1·38–2·50)	1·52 (1·07–2·15)

Data are GM (95% CI); n or GMR (95% CI). GM=geometric mean. GMR=geometric mean ratio. MenB=capsular group B meningococcal. PPD=Pharmaceutical Product Development laboratories. AU=arbitrary units. EU=ELISA units. IC₅₀=half-maximal inhibitory concentration. SFC=spot forming cell. PBMCs=peripheral blood mononuclear cells.

^*GMR between participants aged 12–17 years in the ChAdOx1 nCoV-19 long interval group and participants aged 12–17 years in the ChAdOx1 nCoV-19 short interval group.

^†GMR between participants aged 6–11 years in the ChAdOx1 nCoV-19 group and participants aged 12–17 years in the ChAdOx1 nCoV-19 long interval group.